Retrospective Analysis of Urinary Tract Infection in the Pediatric Population at a Tertiary Care Centre

Naz Perween 1, Sumit Rai 2, Sumi Nandwani 3, Shyam Kishor Kumar II 4

Abstract

Background: Urinary tract infection (UTI) is among the most common infections occurring during childhood. It is caused by both gram-negative and gram-positive bacteria and Escherichia coli is the most common causative agent.

Methods: Data of all pediatric patients in the age group of 6 months to 18 years with urinary tract infection were taken for analysis. Urine samples were collected and cultured on the cystine lactose electrolyte-deficient medium. The presence of bacteria was identified using biochemicals, and the antimicrobial test was performed using the Kirby-Bauer test or the VITEK 2 compact system (bioMérieux, Inc., France).

Results: The prevalence of UTI was 23.5%. In total, 614 specimens tested positive with significant bacteriuria. The male-to-female ratio was 1:2.3. Approximately 54% patients presented with urinary symptoms alone. Culture positivity was significantly associated with pyuria (p < 0.0001). E. coli (354/614) was the most common isolate, followed by Enterococcus spp. (92/614). Colistin, polymyxin B, fosfomycin, nitrofurantoin, netilmicin, and amikacin were extremely good acting antimicrobials. Meanwhile, ampicillin, cefotaxime, ceftriaxone, and norfloxacin were highly resistant to gram-negative bacteria. Multidrug-resistant bacteria and extended-spectrum beta-lactamase-producing bacteria were found in 47% and 44.1% of cases, respectively. Vancomycin, linezolid, teicoplanin, and nitrofurantoin were highly effective against gram-positive bacteria. Furthermore, norfloxacin, trimethoprim/sulfamethoxazole, ciprofloxacin, and tetracycline were highly resistant to gram-positive bacteria. Of the 92, 42 Enterococcus spp. were resistant to high-dose gentamicin.

Conclusion: Nitrofurantoin and amikacin can be used as empirical therapy for gram-negative and gram-positive bacteria. Because resistance to various commonly used antibiotics is found to be increasing, treatment must be guided by antibiotic susceptibility reports.

Introduction

Urinary tract infection (UTI) encompasses clinical conditions ranging from asymptomatic bacteriuria to severe kidney infection, which may progress to sepsis. It is one of the most common infections in the pediatric population that, if not managed appropriately, may progress to different complications such as irreversible renal parenchymal damage and renal scarring. In turn, these can cause hypertension and renal failure. The risks of UTI in childhood are approximately 1%-3% in boys and 3%-10% in girls [1]. Boys are more affected in the first few months of life than girls (2.7% vs 0.7%) [2]. However, the rate decreases thereafter. UTI is commonly characterized by burning micturition, increased urinary frequency, loss of bladder control, low back pain, and bloody or foul-smelling urine [2]. Infants cannot describe their symptoms accurately. Thus, clinicians should be more vigilant when effectively diagnosing and treating this patient group [3]. Conventional culture and sensitivity report is often delayed up to 48-72 h. Moreover, urine sample is challenging to collect in this age group, thereby making the condition more complex to manage. Hence, the treatment approach should be based on empirical therapy [4]. However, in developing countries, there is a lack of local data on antimicrobial profiles. Therefore, most clinicians treat patients according to their experience and disease severity. These random practices of antibiotic administration have posed a selection pressure on bacteria leading to the emergence of multidrug-resistant (MDR) organisms.

To date, several studies have reported about the extended-spectrum beta-lactamases (ESBLs), carbapenem-resistant Enterobacteriaceae, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE) in a significant proportion of individuals [5]. The prevalence of these types of bacteria is increasing and the emergence of these superbugs has limited treatment options. Therefore, drugs should not...
be used based on assumptions. The epidemiological and antibiotic profiles of UTI pathogens significantly differ based on the geographical pattern. Therefore, healthcare facility personnel or treating physicians must be knowledgeable about these pathogens and local antimicrobial profiles. The current study aimed to determine the prevalence of UTI and different bacteria isolated and their antimicrobial resistance profiles, which may be helpful in determining appropriate empirical therapies.

**Materials And Methods**

This data-based study was performed at Post Graduate Institute of Child Health, Noida, India. All pediatric patients with complaints of UTI from the age group of 6 months to 18 years in the outpatient or inpatient department from 2017 to 2019 were included in this analysis. The requisition form received in the microbiology laboratory was used as the data collection tool to document patient details such as admission location of patients in the hospital, age, sex, symptoms, and any specific complications.

Mid-stream clean catch urine specimens were collected in a sterile container from suspected patients and were transported to the laboratory at the earliest (within two hours after collection). Proper instructions regarding sample collection were followed to prevent contamination.

**Culture and identification techniques**

Cystine lactose electrolyte-deficient agar (HiMedia Laboratories, Mumbai) was used to culture urine specimens with a calibrated inoculating loop with a capacity of 0.001 mL. Inoculated plates were incubated for 18-24 h at 37°C aerobically. Plates with a colony count of ≥10⁵ cfu/mL indicated significant bacteriuria [6]. Plates with three or more than three types of bacteria were considered contaminated and were not processed further. We performed further gram staining to assess the colony of interest and other biochemical tests to identify bacterial isolates.

**Antimicrobial susceptibility test**

Bacterial isolates underwent the antimicrobial susceptibility test (AST) using the Kirby-Bauer test or the VITEK 2 compact system (bioMérieux, Inc., France). With the disk diffusion method, three to five colonies were taken to prepare a 0.5 McFarland suspension. Then, a cotton swab was dipped into the suspension and pressed against the tube wall. It was taken out for the inoculation of the Mueller-Hinton agar plate using the lawn culture method. Plates were allowed to dry for three to five minutes, and antibiotic disks were placed on the plates using sterile forceps. These inoculated plates were incubated at 37°C for 18-24 h. Results were interpreted according to the Clinical and Laboratory Standards Institute guidelines, 27th edition [7]. Next, the following antibiotics were tested: amikacin (50 μg), ampicillin (10 μg), ampicillin/subactam (10/10 μg), cefoxitin (50 μg), cefotaxime (30 μg), ceftiraxone (30 μg), ceftazidime (30 μg), cefepime (30 μg), gentamicin (10 μg), high-dose gentamicin (120 μg), imipenem (10 μg), meropenem (10 μg), nitrofurantoin (300 μg), norfloxacin (10 μg), netilmicin (30 μg), piperacillin/tazobactam (100/10 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg), aztreonam (30 μg), ciprofloxacin (5 μg), chloramphenicol (30 μg), tobramycin (5 μg), colistin (10 μg), tetracycline (30 μg), imipenem (10 μg), and linezolid (30 μg).

For VITEK AST, the GN72 and GP71 cards were used for non-sporing gram-negative and gram-positive bacteria, respectively. In the statistical analysis, the intermediate sensitivity results of bacterial isolates were included in the resistant results.

**Quality control**

*Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, *S. aureus* ATCC 25923, and *Enterococcus faecalis* ATCC 29212 strains were used for quality control.

**ESBL detection**

Cefotaxime (30 μg) or ceftazidime (30 μg) was used to screen ESBL-producing organisms. Isolates with a zone diameter of <27 mm for cefotaxime or <22 mm for ceftazidime were further evaluated using the double-disk diffusion method (i.e., cefotaxime 30 μg and cefotaxime/clavulanic acid 30/10 μg, or ceftazidime 30 μg and ceftazidime/clavulanic acid 30/10 μg). Lawn culture was performed on the Mueller-Hinton agar plate from the 0.5 McFarland standard of bacterial suspension. Cefotaxime (30 μg) and cefotaxime/clavulanic acid (30/10 μg) or ceftazidime (30 μg) and ceftazidime/clavulanic acid (30/10 μg) were placed on a plate placed 20 mm apart and were incubated at 37°C for overnight. An increase in the zone diameter of ≥5 mm for either combination was considered as phenotypic confirmation for ESBL-producing organisms [7]. *E. coli* ATCC 25922 and *Refluxella pneumoniae* 700603 were used as ESBL-negative and ESBL-positive reference strains, respectively.

**Statistical analysis**

Data were entered in the Microsoft Excel sheet (Microsoft, Redmond, WA). The GraphPad software (GraphPad Software, San Diego, CA) was used to analyse data. Discrete variables were expressed as
percentages and proportions were compared using the Fisher’s exact test. A p value <0.05 was considered significant.

**Results**

In total, 2,613 specimens were collected from the patients, including 985 men and 1,628 women, during a three-year period. In total, 614 specimens tested positive with significant bacteriuria (either pure or predominant growth), with a prevalence rate of 23.5%. The male-to-female ratio was 1:2.3 (p < 0.0001). Most patients came from the outpatient door (410/614, 66.8%), followed by those from the inpatient door (137/614, 22.3%) and intensive care unit (67/614, 10.9%). The preteen age group (48%) was the most commonly affected, followed by the teen age (34%), infant (11%), and preschool children (7%) groups. Approximately 54% of patients only presented with urinary symptoms such as dysuria and urgency. The other symptoms included fever without urinary symptoms (28%), fever with urinary symptoms (11%), and sepsis (7%) (Table 1).

| Bacteria                          | Number (percentage) |
|----------------------------------|---------------------|
| **Gram-negative bacteria**       |                     |
| *Escherichia coli*               | 334 (54.4%)         |
| *Klebsiella pneumoniae*          | 77 (12.5%)          |
| *Pseudomonas aeruginosa*         | 28 (4.6%)           |
| *Proteus mirabilis*              | 25 (4.1%)           |
| *Morganella morganii*            | 14 (2.3%)           |
| *Alcaligenes faecalis*           | 11 (1.8%)           |
| *Providencia stuartii*           | 8 (1.3%)            |
| *Citrobacter* spp.               | 6 (0.9%)            |
| *Salmonella Paratyphi A*         | 2 (0.3%)            |
| *Serratia marcescens*            | 2 (0.3%)            |
| *Acinetobacter* spp.             | 2 (0.3%)            |
| *Pantoea agglomerans*            | 1 (0.16%)           |
| *Enterobacter*                   | 1 (0.16%)           |
| *Burkholderia cepacia*           | 1 (0.16%)           |
| **Gram-positive bacteria**       |                     |
| *Enterococcus faecium*           | 89 (14.5%)          |
| *Enterococcus faecalis*          | 3 (0.5%)            |
| *Staphylococcus aureus*          | 9 (1.5%)            |
| *Streptococcus*                  | 1 (0.16%)           |

**TABLE 1: Bacterial isolates from urine samples**

In total, 418 patients presented with pyuria without culture positivity, and 550 patients had pyuria with culture positivity (p < 0.0001). The gram-negative bacteria (512/614) outnumbered the gram-positive bacteria (102/614). *E. coli* (334/614) was the most common isolate, followed by *Enterococcus* spp. (92/614). The other common bacteria were *K. pneumoniae* (77/614), *P. aeruginosa* (28/614), *Proteus mirabilis* (25/614), *Morganella morganii* (14/614), *Alcaligenes faecalis* (11/614), *S. aureus* (9/614), and *Providencia stuartii* (8/614) (Table 2).
| Variables          | Frequency | Percentage |
|-------------------|-----------|------------|
| Sex               |           |            |
| Boys              | 186       | 30.3%      |
| Girls             | 428       | 69.7%      |
| Age (years)       |           |            |
| <1                | 67        | 11%        |
| 1–5               | 43        | 7%         |
| 6–12              | 295       | 48%        |
| 13–18             | 209       | 34%        |
| Location of admission |       |            |
| OPD               | 410       | 66.8%      |
| IPD               | 137       | 22.3%      |
| ICU               | 67        | 10.9%      |
| Symptoms          |           |            |
| Urinary symptoms alone | 333   | 54%        |
| Fever without urinary symptoms | 171  | 28%        |
| Fever with urinary symptoms | 67   | 11%        |
| Sepsis            | 43        | 7%         |

**TABLE 2: General characteristics of patients**

Several antibiotics were tested against both gram-negative and gram-positive bacteria. The gram-negative bacteria were least resistant to colistin, polymyxin B, fosfomycin, nitrofurantoin, netilmicin, and amikacin and were highly resistant to ampicillin, cefotaxime, ceftriaxone, and norfloxacin (Figure 1). The four most common isolated gram-negative bacteria were showing good sensitivity for carbapenems. *P. aeruginosa* were highly resistant to commonly used cephalosporins like cefepime and ceftazidime (Table 3). A total of 240 (47%) bacteria were resistant to multiple drugs (three or more group of antibiotics). In total, 271 (44.1%) bacteria were ESBL producing, and among them, 221 (81.6%) were *E. coli*. 
**FIGURE 1:** Antibiotic resistant profile of gram-negative bacteria (%)

| Antibiotics          | *Escherichia coli* | *Klebsiella pneumoniae* | *Proteus mirabilis* | *Pseudomonas aeruginosa* |
|----------------------|--------------------|-------------------------|---------------------|--------------------------|
| Ampicillin           | 94.4%              | 92.9%                   | 63.2%               | -                        |
| Cefotaxime           | 85.4%              | 63.3%                   | 59.1%               | -                        |
| Ceftriaxone          | 85.4%              | 25%                     | 50%                 | -                        |
| Norfloxacin          | 84%                | 55.7%                   | 50%                 | 38.4%                    |
| Cefixime             | 80%                | -                       | -                   | -                        |
| Ciprofloxacin        | 77.2%              | 33.3%                   | 85.7%               | 42.3%                    |
| Trimethoprim-sulfamethoxazole | 75%     | 55%                     | 55.6%               | -                        |
| Aztreonam            | 72.6%              | 52%                     | 30.4%               | 44%                      |
| Cefepime             | 53.8%              | 100%                    | 60%                 | 57.7%                    |
| Ceftazidime          | 50%                | 0                       | 66.7%               | 64.3%                    |
| Ampicillin-sulbactam | 48.1%              | 52.1%                   | 9.5%                | -                        |
| Gentamicin           | 41.7%              | 0                       | 66.7%               | 62.5%                    |
| Piperacillin-tazobactam | 40.1%  | 35.4%                   | 0                   | 42.3%                    |
| Imipenem             | 39.4%              | 31.7%                   | 35%                 | 34.6%                    |
| Meropenem            | 30.5%              | 30.8%                   | 4%                  | 29.6%                    |
| Amikacin             | 24.6%              | 23.5%                   | 29.2%               | 37%                      |
| Netilmicin           | 14.5%              | 23.8%                   | 29.4%               | 38.9%                    |
| Nitrofurantoin       | 4.8%               | 24.9%                   | 100%                | 50%                      |
| Fosfomycin           | 1.5%               | 3.2%                    | 12.5%               | -                        |
| Colistin             | 0                  | 0                       | 100%                | 7.4%                     |
| Polymyxin B          | 0                  | 0                       | 100%                | 5%                       |

**TABLE 3:** Antibiotic resistant patterns of commonly isolated gram-negative bacteria
Vancomycin, linezolid, teicoplanin, and nitrofurantoin were least resistant to gram-positive bacteria. However, antibiotics such as norfloxacin, trimethoprim/sulfamethoxazole, ciprofloxacin, and tetracycline were highly resistant (Figure 2). Of 92, 42 Enterococcus spp. were resistant to high-dose gentamicin (Table 4).

![Antibiotic resistant profiles of gram-positive bacteria (%)](image)

**FIGURE 2: Antibiotic resistant profiles of gram-positive bacteria (%)**

**TABLE 4: Antibiotic resistant patterns of commonly isolated gram-positive bacteria**

| Antibiotics                  | *Enterococcus* spp. (92) | *Staphylococcus* aureus (9) |
|------------------------------|--------------------------|----------------------------|
| Netilmicin                   | -                        | 0                          |
| Norfloxacin                  | 100%                     | 100%                       |
| Ciprofloxacin                | 85.1%                    | -                          |
| Trimethoprim-sulfamethoxazole| -                        | 100%                       |
| Cefoxitin                    | -                        | 62.5%                      |
| Tetracycline                 | 80.5%                    | 0                          |
| Ampicillin                   | 45.5%                    | -                          |
| Gentamicin                   | -                        | 33.3%                      |
| High-dose gentamicin         | 45.1%                    | -                          |
| Nitrofurantoin               | 8.9%                     | 0                          |
| Teicoplanin                  | 6.5%                     | 0                          |
| Vancomycin                   | 1.2%                     | 0                          |
| Amikacin                     | -                        | 22.2%                      |
| Linezolid                    | 0                        | 0                          |

**Discussion**

This study found that the prevalence rate of UTI in the pediatric population was 23.5%. Different studies have reported prevalence rates as low as 7.8% in Iran [8] and 9% in the USA [9] and as high as 16% in Nepal [10], 26.45% in Ethiopia [2], and 21.2% and 26.7% in India [1,11]. Thus, the prevalence in our study was correlated with that of developing countries. In our study, women were more significantly affected than men, and this finding was observed in other studies as well [2,12]. The close proximity of the urethra to the
The current study had several limitations. We did not include risk factors associated with UTI. In fact, increasing S. aureus it had good sensitivity to vancomycin, linezolid, teicoplanin, and amikacin (Table 1). Moreover, we did not perform molecular tests to correlate the findings with antibiotic resistant patterns. In 76% of cases, pyuria was observed (p < 0.0001), and this result is in contrast to that of the study by Tryphena et al. that revealed that pyuria was only observed in 22.5% of cases [1]. This microscopic finding may act as a guiding tool to start empirical therapy based on the local anti-biogram, which needs to be changed after obtaining the urine culture and antimicrobial susceptibility report of patients.

Gram-negative bacteria are common intestinal habitants. Thus, they can easily colonize the perineal and periurethral area. This colonization is further facilitated by the additional structures of bacteria including flagella and pili, which are helpful for attachment with the uroepithelium and increases the risk of infection [14]. Hence, several studies showed that gram-negative bacteria are more predominant than gram-positive bacteria [2,3,14]. Furthermore, our finding is in accordance with that of other studies as we isolated 83.4% of gram-negative bacteria as pathogens. E. coli was the most common isolate responsible for 54.4% of infectious cases, and this finding is in accordance with that of several studies [1,5,10,14]. Enterococcus faecium was the second most common isolate in our study. Tryphena et al. and Shrestha et al. also isolated Enterococcus spp, and it was considered the second most common isolate [1,10].

In our study, gram-negative rods (GNRs) were very highly resistant to ampicillin (91.4%) and cotrimoxazole (68%), and this result was in agreement with that of other studies [1,2,15,16]. The emergence of resistance to these antibiotics might be attributed to their easy availability and frequent use as empirical therapy [2]. Our study found that GNRs were highly resistant to third- and fourth-generation cephalosporins and ciprofloxacin, which is similar to the study of Kaur et al. [16]. This might be attributed to the fact that cephalosporins and fluoroquinolones are commonly used, thereby resulting in bacteria resistance to these drugs. However, some studies have reported that cephalosporins and ciprofloxacin are sensitive drugs [2,15]. This finding may be attributed to different geographical locations and different medicinal practices. Nitrofurantoin was among the most effective antibiotics in our study. This finding is similar to that of other studies. Hence, it can be considered as empirical therapy [1,10,11,16]. Amikacin, piperacillin/tazobactam, and carbapenems also had good sensitivity, which was also observed in other studies [1,11,16]. More than 50% of GNRs were resistant to gentamicin. However, the study by Seifu and Gebissa had contrasting results, as more than 90% of GNRs were found to be sensitive to gentamicin [17]. Compared with E. coli, K. pneumoniae was more sensitive to ceftriaxone and ciprofloxacin and more resistant to nitrofurantoin in our study (Table 3).

We found that 47% of bacteria were multidrug resistant. This is alarming, and shows the inappropriate use of antibiotics in the community and healthcare facilities, lack of proper antibiotic policies, and an increased prevalence of resistant genes in bacteria. Several studies have reported a higher prevalence of MDR organisms [10,14]. In our study, ESBLs accounted for 44.1% of all organisms, which is similar to several studies [1,10,18]. However, some studies such as that conducted by Wu et al. found that only 14% of bacteria were ESBLs, and this value was significantly lower [19]. The increasing prevalence of ESBLs may be attributed to the increasing use of third-generation cephalosporin, thereby causing antibiotic selection pressure [20]. Multiple factors affect the prevalence of ESBLs such as transmissibility of ESBL strains in the community and healthcare facilities, environmental stress, and increased and inappropriate use of carbapenems, third-generation cephalosporins, and quinolones. The location of the ESBL gene on the plasmid and other mobile genetic elements facilitate the transmission of the resistant property among bacteria for multiple antibiotics, and this is another important factor [14]. The increasing percentage of ESBLs in the pediatric population limits the therapeutic options. Thus, this poses serious threat in this patient group [19].

Gram-positive bacteria were found to be highly sensitive to vancomycin, linezolid, teicoplanin, and nitrofurantoin and highly resistant to ciprofloxacin, norfloxacin, cotrimoxazole, and tetracycline in our study (Figure 2). Enterococcus spp. was 100% resistant to norfloxacin and highly resistant to ciprofloxacin and tetracycline (Table 4). Nitrofurantoin had a good mechanism of action against Enterococcus spp., and this finding is similar to that of the study conducted by Tryphena et al. However, ampicillin and high-dose gentamicin were highly resistant, which is contrary to the study results of Tryphena et al. [1]. We found VRE in 1.2% of the total Enterococcus spp. Different studies have shown different results. Shrestha et al. reported 5% VRE in their study while Tryphena et al. did not find any VRE [1,10]. Pouladfar et al. reported an extremely high VRE at 71.4% [21]. S. aureus was 100% resistant to norfloxacin and cotrimoxazole. However, it had good sensitivity to vancomycin, linezolid, teicoplanin, and amikacin (Table 4). In our study, 62.5% of S. aureus were methicillin resistant. Numerous studies have shown that the prevalence of MRSA in UTI is increasing [10,22]. Amikacin and gentamicin were effective against S. aureus.

The current study had several limitations. We did not include risk factors associated with UTI. In fact, different risk factors such as congenital anomaly or circumcision affect microbiological profiles and antibiotic resistant patterns. Moreover, we did not perform molecular tests to correlate the findings with antibiotic resistance patterns.
Conclusions

*Escherichia coli* followed by *Enterococcus* spp. are the most common isolates of UTI. Based on this study, both gram-negative and gram-positive bacteria have a good sensitivity to nitrofurantoin and amikacin. Hence, they can be used as empirical therapy. Higher generation antibiotics such as carbapenem and colistin for gram-negative bacilli and vancomycin and linezolid for gram-positive cocci show better efficacy. However, some strains show resistant to these drugs. The prevalence of MDR and ESBL-producing bacteria is increasing. Thus, it is extremely important to use our repertoire judiciously. Furthermore, antibiotic resistance varies in different geographical locations. Hence, a local antibiogram should be followed to use for empirical therapy.

Additional Information

Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/sponsorship info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Triyaphena C, Sahni RD, John S, Jeyquaa S, George A, Helan J: A retrospective study on the microbial spectrum and antibiogram of uropathogens in children in a secondary care hospital in Rural Vellore, South India. *J Family Med Prim Care*. 2021, 10:1706-11. 10.4105/jfmpc.jfmpc_2090.20
2. Ayelela B, Abebe B, Shibeshi A, et al.: Bacterial isolates and their antimicrobial susceptibility patterns among pediatric patients with urinary tract infections. *Turk J Urol*. 2018, 44:62-9. 10.5152/tuj.2017.33678
3. Vélez Echeverri C, Serna-Higueta LM, Serrano AR, et al.: Resistance profile for pathogens causing urinary tract infection in a pediatric population, and antibiotic treatment response at a University Hospital, 2010-2011. *Colombia Medica*. 2014, 45:39-44. 10.25100/cmc.v45i1.1518
4. Mitiku E, Amsalu A, Tadesse BT: Pediatric urinary tract infection as a cause of outpatient clinic visits in southern Ethiopia: a cross sectional study. *Etiop Health Sci*. 2018, 28:187-96. 10.4314/ejhs.v28i2.10
5. Jayaweeza JA, Reyes M: Antimicrobial misuse in pediatric urinary tract infections: recurrences and renal scarring. *Ann Clin Microbiol Antimicrob*. 2018, 17:27. 10.1186/s12941-018-0279-4
6. Demilie T, Beyene G, Melaku S, Tsegaye Y: Urinary bacterial profile and antibiotic susceptibility pattern among pregnant women in North West Ethiopia. *Etiop Health Sci*. 2012, 22:79277.
7. CLSI: Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI Supplement M100. 2017 (ed): Clinical and Laboratory Standards Institute, Wayne, PA; https://clsi.org/media/1469/m100s27_sample.pdf.
8. Zorc JJ, Levine DA, Platt SL, et al.: Clinical and demographic factors associated with urinary tract infection in young febrile infants. *Pediatrics*. 2005, 116:644-8. 10.1542/peds.2004-1825
9. Mirsoleymani SB, Salimi M, Shareghi Brojeni M, Ranjbar M, Mehtapoor M: Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012). *Int J Pediatr*. 2014, 2014:126142. 10.1155/2014/126142
10. Shrestha LB, Baral R, Poudel P, Khanal B: Clinical, etiological and antimicrobial susceptibility profile of pediatric urinary tract infections in a tertiary care hospital of Nepal. *BMC Pediatr*. 2019, 19:36. 10.1186/s12887-019-1410-1
11. Badhan R, Singh DV, Badhan LR, Kaur A: Evaluation of bacteriological profile and antibiotic sensitivity patterns in children with urinary tract infection: a prospective study from a tertiary care center. *Indian J Urol*. 2016, 32:50-6. 10.4103/0970-1591.173118
12. Giri A, Kaffe R, Singh GK, Niraula N: Prevalence of E. coli in urinary tract infection of children aged 1-15 years in a medical college of Eastern Nepal. *JNMA J Nepal Med Assoc*. 2020, 58:11-4.
13. Merga Duffa Y, Terfa Kitiia K, Mamuye Gebretsadik D, Bitew A: Prevalence and antimicrobial susceptibility of bacterial uropathogens isolated from pediatric patients at Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia. *Int J Microbiol*. 2018, 2018:8492309. 10.1155/2018/8492309
14. Fenta A, Dagnew M, Eshetie S, Belachew T: Bacterial profile, antibiotic susceptibility pattern and associated risk factors of urinary tract infection among clinically suspected children attending for Felege Hiwot comprehensive and specialized hospital, Northwest Ethiopia. A prospective study. *BMC Infect Dis*. 2020, 20:675. 10.1186/s12879-020-05402-y
15. Belete Y, Asrat D, Woldeamarnuel Y, Yihnew G, Gize A: Bacterial profile and antibiotic susceptibility pattern of urinary tract infection among children attending Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. *Infect Drug Resist*. 2019, 12:5575-83. 10.2147/IDR.S217574
16. Kaur N, Sharma S, Malhotra S, Madan P, Hans C: Urinary tract infection: aetiology and antimicrobial resistance pattern in infants from a tertiary care hospital in northern India. *J Clin Diagn Res*. 2014, 8:DC01-3. 10.7860/JCDR/2014/8772.4919
17. Seifu WD, Gebissa AD: Prevalence and antibiotic susceptibility of Uropathogens from cases of urinary tract infections (UTI) in Shashemene referral hospital, Ethiopia. *BMC Infect Dis*. 2018, 18:30. 10.1186/s12879-017-2911-z
18. Fatima S, Muhammad IN, Umman S, Jamil S, Khan MN, Khan SI: Incidence of multidrug resistance and
extended-spectrum beta-lactamase expression in community-acquired urinary tract infection among different age groups of patients. Indian J Pharmacol. 2018, 50:69-74. 10.4103/ijp.IJP_200_17

19. Wu CT, Lee HY, Chen CL, Tuan PL, Chiu CH: High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. J Microbiol Immunol Infect. 2016, 49:243-8. 10.1016/j.mii.2015.05.016

20. Pouladfar G, Jafarpour Z, Hosseini SA, Janghorban P, Roozbeh J: Antibiotic selective pressure and development of bacterial resistance detected in bacteriuria following kidney transplantation. Transplant Proc. 2015, 47:1151-5. 10.1016/j.transproceed.2014.11.062

21. Pouladfar G, Basiratnia M, Anvarinejad M, Abbasi P, Amirmoezi F, Zare S: The antibiotic susceptibility patterns of uropathogens among children with urinary tract infection in Shiraz. Medicine (Baltimore). 2017, 96:e7834. 10.1097/MD.0000000000007834

22. Looney AT, Redmond EJ, Davey NM, Daly PJ, Troy C, Carey BF, Cullen IM: Methicillin-resistant Staphylococcus aureus as a uropathogen in an Irish setting. Medicine (Baltimore). 2017, 96:e4635. 10.1097/MD.0000000000004635